In recent times, this therapeutic approach has revolutionized cancer immunotherapy, and as a result, immunotherapeutics have led to extraordinary increases in overall survival of patients, first with anti-CTLA-4 antibody and subsequently with anti-PD-L1 antibodies, in lung cancer, melanoma, and other malignancies [7,8]. Here, CD274 is linked to lung cancer.